

Newspaper Name	Economic Times
Date	9-11-08
Page	3
Description	Super Religare Labs ties up with Norwegian biotech co

Super Religare Labs ties up with Norwegian biotech co

New Delhi: Super Religare Laboratories, formerly SRL Ranbaxy, has tied up with Norwegian biotechnology company DiaGenic to launch the world's first early breast cancer detection test. The test will be priced Rs 10,000-20,000 but the company plans to reduce the cost soon after the volumes increases. "India will be first country to benefit from this test beginning with our centres in Delhi and NCR. The test is a patented product in India and we will soon offer the service nationwide," said Super Religare Laboratories CEO Sanjeev Chaudhry. DiaGenic conducted trials of the test in 750 women in India. Breast cancer is the second most common form of cancer amongst Indian women. About one lakh women died from breast cancer in India in 2007, and is expected touch over 2 lakh by the end of 2015.